Search Results

You are looking at 121 - 130 of 383 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Lainie Martin and Russell J. Schilder

. The safety of bevacizumab . Expert Opin Drug Saf 2006 ; 5 : 289 – 301 . 13. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy . Nat Med 2001 ; 7 : 987 – 989 . 14

Full access

Presented by: Mitesh J. Borad

,” commented Dr. Borad. Immunotherapy The combination of antiangiogenics with immune checkpoint inhibitors (atezolizumab + bevacizumab) is a recommended option for certain patients. “We know that hepatocellular cancers have a tumor microenvironment in a

Full access

Presented by: Robert I. Haddad

According to Dr. Haddad, other research looking at targets besides immunotherapy has been “disappointing.” A long-running phase III trial of chemotherapy with or without bevacizumab in patients with recurrent/metastatic HNSCC showed no statistically

Full access

Denise Leung, Xiaosi Han, Tom Mikkelsen, and L. Burt Nabors

/print certificate. Release date: November 4, 2014; Expiration date: November 4, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the challenges of MRI assessment in patients receiving bevacizumab

Full access

Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, and Benjamin R. Tan

erlotinib plus bevacizumab. Response to Gemcitabine-Based Treatments A total of 88% of patients (50/57) who received a gemcitabine-based regimen were evaluable for response ( Table 2 ), including 37 of 41 patients who received gemcitabine

Full access

Matthias Holdhoff and Marc C. Chamberlain

trial. 35 The results of AVAglio and RTOG 0825, 2 studies examining the addition of bevacizumab to radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, were recently presented. 39 , 40 Neither study showed an OS advantage with

Full access

Wells A. Messersmith

to determine benefit from adjuvant chemotherapy; there is a similar lack of data for ‘high-risk’ stage II disease and benefit from adjuvant chemotherapy.” 3 Finally, adding the biologic bevacizumab or cetuximab did not appear to offer an advantage

Full access

Melinda Telli

German GeparSixto study, 1 the inclusion of carboplatin improved the pathologic complete response (pCR) rate compared with paclitaxel, nonpegylated liposomal doxorubicin, and bevacizumab used alone among those patients with triple-negative breast cancer

Full access

Bruce D. Minsky, Claus Rödel, and Vincenzo Valentini

benefit of adding targeted biologic agents, such as bevacizumab and cetuximab, is being tested. Initial phase I/II trials of bevacizumab plus preoperative 5-FU or capecitabine-based chemoradiation revealed pCR rates of 18% to 24%. 17 , 18 However, more

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang

, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 40 Yang JC Haworth L Sherry RM . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal